Schizophrenia/Psychosis

Adherence, switching, and quality of life are top concerns in BDI, and schizophrenia.

Vanda Pharmaceuticals has submitted an NDA for approval of Bysanti for the treatment of acute bipolar I disorder and schizophrenia.

A schizophrenia research expert weighs in on the recent announcement concerning SPG302 for the treatment of individuals with schizophrenia.

LB Pharmaceuticals presented additional positive data from NOVA1 exploring LB-102 in patients with acutely exacerbated schizophrenia, at the 2025 Annual Congress of the Schizophrenia International Research Society.

Spinogenix announced open enrollment for the phase 2 trial of SPG302, the first synaptic regenerative approach to treat schizophrenia with the potential to improve outcomes across all symptom domains.

In this exclusive interview with Psychiatric Times, John Kane, MD, shares more on the new positive data on LB-102 for the treatment of acutely exacerbated schizophrenia.

The prevalence of tobacco use in schizophrenia is over 60%—3 times that of the general population. However, the reason for the high prevalence of tobacco use in schizophrenia remains largely unknown.

While the removal of the REMS requirement can be liberating, appropriate monitoring for patients with schizophrenia is still of the utmost importance.

The FDA decision to remove the clozapine REMs requirement has left many questions. Chelsie Monroe, MSN, APN, PMHNP-BC, sheds some light on it.

Chelsea Monroe, MSN, APN, PMHNP-BC, discusses the current renaissance in treating schizophrenia.

Celebrate our 40th anniversary with Gustavo Alva, MD, FAPA, our Mood Disorders Section Editor.

Increased awareness of catatonia and its treatment among health care providers, especially in underresourced areas, is essential for improving patient outcomes.

In a survey capturing the lived experiences of individuals with schizophrenia on antipsychotic medications, 27% of participants reported that antipsychotics had done “more harm than good.”

Postpartum psychosis occurs in about 1 to 2 per thousand new mothers. In this personal story, one writer shares her experience with postpartum psychosis.

Do you want to be featured in a future Special Report? Check out our March theme!

The president of Black Psychiatrists of America shares his thoughts on making a difference for Black communities, the removal of the REMS for clozapine, and more.

A new study from Mount Sinai Health System and IBM Research is investigating the use of AI in developing objective measures for psychiatric diagnoses.

Determining risks outweigh the benefits, the FDA is removing the clozapine REMS requirement.

Cannabis use disorder and schizophrenia both peak in prevalence around the same age. Is there a cause-and-effect relationship?

Here are highlights from this week in Psychiatric Times, including trial updates and thoughts on the history of the antimedication movement.

What are the top 6 disappointing psychopharmacological updates from the past year? We rank the top 6.

Consideration of both practical and ethical concerns, as well as an interdisciplinary approach, can lead to better outcomes for pregnant patients with psychosis.

Catch up on coverage from the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update.

Recent research demonstrated that xanomeline-trospium is more efficacious than placebo in treating positive and negative psychotic symptoms in adults with schizophrenia.

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

Facing limited resources, cultural barriers, and complex mental health cases, A newly qualified doctor’s year in rural South Africa offers a deep dive into psychiatry in underserved areas.

How can we get back to recovery as the treatment goal for schizophrenia?

2024 into 2025: a period of highs and lows for schizophrenia treatment.

Digital therapeutics may help improve negative symptoms associated with schizophrenia.

Although iclepertin was found to be well tolerated, the agent did not meet endpoints.